The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > COLUMN
COLUMN
-
Our Habits Determine Our Success
August 8, 2012
-
Marketing Is More than a Pen and a Tissue Box
July 9, 2012
-
Science without Works Is Dead
June 4, 2012
-
Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
-
The Eight Characteristics of a Great Leader
April 2, 2012
-
Maurer’s Healthcare Insight (143)
March 26, 2012
-
Maurer’s Healthcare Insight (142)
February 27, 2012
-
Maurer’s Healthcare Insight (141)
January 30, 2012
-
Maurer’s Healthcare Insight (140)
December 26, 2011
-
Maurer’s Healthcare Insight (139)
December 12, 2011
-
Maurer’s Healthcare Insight (138)
November 21, 2011
-
Maurer’s Healthcare Insight(137)
October 17, 2011
-
Maurer’s Healthcare Insight (136)
September 12, 2011
-
Maurer's Healthcare Insight (135)
August 15, 2011
-
Maurer's Healthcare Insight (134)
August 1, 2011
-
Maurer's Healthcare Insight (133)
July 11, 2011
-
Maurer's Healthcare Insight (132)
May 30, 2011
-
Maurer's Healthcare Insight (131)
April 18, 2011
-
Maurer's Healthcare Insight (130)
January 24, 2011
-
Maurer's Healthcare Insight (129)
January 3, 2011
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…